# Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC

> **NCT00181532** · PHASE2 · COMPLETED · sponsor: **Maastricht Radiation Oncology** · enrollment: 102 (—)

## Conditions studied

- Non Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Celecoxib

## Key facts

- **NCT ID:** NCT00181532
- **Lead sponsor:** Maastricht Radiation Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** —
- **Final completion:** 2008-01
- **Target enrollment:** 102 (—)
- **Last updated:** 2009-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00181532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00181532, "Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00181532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*